Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success tags : Phase 3 save search
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Published: 2022-04-27 (Crawled : 13:20) - biospace.com/
ACHV | $4.405 -1.01% -1.02% 63K
|
Health Technology
|
| O: -2.43%
H: 8.03%
C: 2.91%
trial results phase 3
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
NBIO J | $0.1197 15.32% 300
|
|
| O: 0.17%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3 cancer train
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
MNMD | $9.88 1.02% 1.01% 930K
|
n/a
|
| O: -1.32%
H: 1.33%
C: -1.33%
trial phase 1 phase 2 phase 3
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.27 -9.92% -11.01% 550K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | $265.64 0.05% 0.05% 2M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac ConductionStudy Supports Ongoing Phase 3 Program and Planned NDA Submission
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
VRNA | $16.21 2.6% 2.53% 550K
|
Health Technology
|
| O: 0.87%
H: 11.26%
C: 9.74%
cardiac ongoing phase 3 submission
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published: 2021-11-15 (Crawled : 09:00) - biospace.com/
JNJ | $144.45 -2.13% 0.03% 13M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ADXN | $22.25 -10.1% -11.24% 21K
|
Health Technology
|
| O: 2.85%
H: 1.14%
C: 1.14%
phase 1 phase 2 xin phase 3
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
Published: 2021-11-09 (Crawled : 14:00) - globenewswire.com
SCYX | $1.41 -4.08% -4.26% 110K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3
Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence® Oral Leuprolide
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
SWKH | $17.22 0.81% 3.9K
|
Miscellaneous
|
| O: -0.76%
H: 5.82%
C: 3.62%
biopharma phase 1 trial phase 3 phase 2
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramPhase 3 Study on Track to Initiate in Second Half 2021
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
RARE | $42.32 -1.28% -1.3% 890K
|
Health Technology
|
| O: 0.39%
H: 2.14%
C: -0.64%
fda phase 2 gene therapy therapy phase 3 gene therapies designation
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
Published: 2021-03-16 (Crawled : 14:00) - biospace.com/
PLRX | $13.24 -2.29% -2.34% 430K
|
Health Technology
|
| O: 1.12%
H: 2.4%
C: -0.41%
phase 1 phase 3 phase 2
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Published: 2021-02-24 (Crawled : 14:01) - globenewswire.com
LGVN P 3 d | $3.49 19.11% 16.05% 9.4M
|
|
| O: 0.47%
H: 20.74%
C: 18.42%
heart phase 1 injection phase 3 phase 2 syndros lomecel-b
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2021-01-25 (Crawled : 13:00) - globenewswire.com
ABEO | $7.83 2.49% 2.43% 220K
|
Health Technology
|
| O: 4.72%
H: 5.41%
C: 4.95%
fda phase 3
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in AcneCompany on track to initiate the TRILOGY Phase 3 program in 2021
Published: 2020-12-17 (Crawled : 15:00) - biospace.com/
VYNE | $2.445 -4.86% -5.11% 33K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: -3.65%
fda acne phase 3 phase 2
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
Published: 2020-12-15 (Crawled : 21:01) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 3.88%
H: 1.08%
C: 0.24%
trial expansion phase 3 phase 1 phase 2
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.